ID
14780
Description
A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01); ODM derived from: https://clinicaltrials.gov/show/NCT00520637
Link
https://clinicaltrials.gov/show/NCT00520637
Keywords
Versions (1)
- 4/27/16 4/27/16 -
Uploaded on
April 27, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Advanced Solid Tumors NCT00520637
Eligibility Advanced Solid Tumors NCT00520637
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
medical illness
Data type
boolean
Alias
- UMLS CUI [1]
- C0262926
Description
central nervous system (cns) tumor involvement
Data type
boolean
Alias
- UMLS CUI [1]
- C0085136
Description
active diarrhea
Data type
boolean
Alias
- UMLS CUI [1]
- C0011991
Description
coagulation disorder
Data type
boolean
Alias
- UMLS CUI [1]
- C0005779
Description
cytochrome p450 3a4
Data type
boolean
Alias
- UMLS CUI [1]
- C3830625
Description
ketoconazole
Data type
boolean
Alias
- UMLS CUI [1]
- C0022625
Description
chemotherapy, immunotherapy
Data type
boolean
Alias
- UMLS CUI [1]
- C0392920
- UMLS CUI [2]
- C0021083
Similar models
Eligibility Advanced Solid Tumors NCT00520637
- StudyEvent: Eligibility
C0024299 (UMLS CUI [2])
C0021083 (UMLS CUI [2])